An artificial intelligence company focused on accelerating pharmaceutical research has completed a Series A funding round worth $110 million, marking its emergence from stealth mode less than a year ago. Boltz, which traces its origins to MIT but has since relocated to London, operates a team of 40 AI researchers in the King's Cross neighbourhood.

Bessemer Venture Partners anchored the financing round, joined by returning backers Andreessen Horowitz, Amplify Partners, Zetta Venture Partners and Obvious Ventures. The new investor cohort encompasses Greycroft, F-Prime Capital, Hummingbird and Benchling, alongside Nvidia, which committed capital during a separate investment announced earlier in the year following Jensen Huang's UK visit. The company had previously secured $28 million in seed funding at the beginning of the year.

What Boltz does

The startup has developed computational tools that enable researchers in pharmaceutical and biotech settings to generate potential drug candidates and prioritise which compounds warrant laboratory testing. Its machine learning models perform several critical functions: they can visualise how protein structures and drug molecules interact when combined, quantify binding strength between molecules, and generate novel molecular structures optimised to attach to specific targets. The company distributes both publicly available models and proprietary solutions via its own platform and application programming interface.

During its time at MIT, the founding team released open-source models that achieved performance parity with proprietary systems developed by DeepMind, including AlphaFold3. These models have since become standard tools in early-stage drug discovery workflows.

Industry partnerships and business model

Boltz has established working relationships with major pharmaceutical firms including Pfizer, GSK, Takeda and Bristol Myers Squibb. The company generates revenue through partnership agreements and by licensing access to its computational platform and AI models.

Next steps

The company intends to deploy the new capital toward expanding computational infrastructure and data resources, as well as growing its workforce.

We believe we are still just at the beginning of an exponential trajectory in model capabilities. Our upcoming models are already showing substantial improvements in the quality of the molecules they generate. Our long-term goal remains a world where a scientist can go from a therapeutic hypothesis to a human-ready molecule without leaving their computer. Reaching that goal will require further advances in the models and substantial investment in compute and data.

Boltz

Source: Tech.eu